Quantcast FATE THERAPEUTIC RG Stock Quote | Stock Price for FATE | Financial News | myMotherLode.com

Financial News

Motherlode Stocks
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
FATE THERAPEUTIC RG (NQ: FATE)
11.14 USD  -0.15 (-1.33%)
Streaming Delayed Price  /  Updated: 3:07 PM EDT, Apr 23, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 240,936
Open 11.30
Bid (Size) 11.13 (300)
Ask (Size) 11.15 (300)
Prev. Close 11.29
Today's Range 11.05 - 11.55
52wk Range 2.520 - 14.45
Shares Outstanding 52,772,056
Dividend Yield N/A
Performance
YTD
+76.83%
+76.83%
1 Month
+2.01%
+2.01%
3 Month
+34.38%
+34.38%
6 Month
+164.61%
+164.61%
1 Year
+142.17%
+142.17%
Top News
More News
Fate Therapeutics Announces Off-the-Shelf CAR T-cell Cancer Immunotherapy to be Featured at 2018 AACR Annual Meeting Press Program
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today... Read More
from GlobeNewswire News Releases
Fate Therapeutics Announces Initial Clinical Data of FATE-NK100 for Recurrent Ovarian Cancer at the Innate Killer Summit 2018
Stable Disease with Tumor Shrinkage Reported in Subject 2 Following Single Dose of NK100 Read More
from GlobeNewswire News Releases
More News
Read More
Recent Analysis Shows EPAM, Sibanye Gold, Fate Therapeutics, Howard Hughes, CBL & Associates Properties, and Quorum Health Market Influences — Renewed Outlook, Key Drivers of Growth
from GlobeNewswire News Releases
Technical Perspectives on Biotech Stocks -- Eyegate Pharma, Fate Therapeutics, FibroGen, and Genocea Biosciences
from PR Newswire
Fate Therapeutics Announces Additional Clinical Data from Phase 1 Stage of PROTECT Clinical Trial of ProTmune™
from GlobeNewswire News Releases
Fate Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Operational Progress
from GlobeNewswire News Releases
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2017 Financial Results
from GlobeNewswire News Releases
Fate Therapeutics Announces Receipt of CIRM Grant for Clinical Translation of FT516 Off-the-Shelf Engineered NK Cell Cancer Immunotherapy
from GlobeNewswire News Releases
BRIEF-Fate Therapeutics Announces Additional Clinical Data From Phase 1 Stage Of Protect Clinical Trial Of Protmune
category companyNews
from Reuters: Company News
Sector Internals + Best Performing Russell 3,000 And S&P 500 Stocks YTD (2018)
category Stocks / Equities
from Blogs - TalkMarkets
Morning Call For Tuesday, March 6
category Bonds , Currencies/Forex , Commodities , and 1 more.
from Blogs - TalkMarkets
Stock Market JSON API provided by www.cloudquote.net
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Follow myMotherLode.com at these social networks Make Us Your Homepage Today Follow us on Facebook Follow us on Twitter Follow us on Youtube Follow us on LinkedIn Follow our RSS Feed
Yellow Pages

Popular Searches

Local Radio Stations
© Copyright 2000-2017 Clarke Broadcasting Corporation. All rights reserved.